1-Methyl-4-(pyrrolidin-2-yl)piperidine → 2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-9-(2-(1-methylpiperidin-4-yl)pyrrolidin-1-yl)-5,6-dihydroimidazo[1,2-d]pyrido[3,4-f][1,4]oxazepine

HRID 1530487Notes

Reaction equation

Cl[C:2]1[CH:3]=[C:4]2[C:13](=[CH:14][N:15]=1)[C:12]1[N:8]([CH:9]=[C:10]([C:16]3[N:20]([CH:21]([CH3:23])[CH3:22])[N:19]=[CH:18][N:17]=3)[N:11]=1)[CH2:7][CH2:6][O:5]2.[CH3:24][N:25]1[CH2:30][CH2:29][CH:28]([CH:31]2[CH2:35][CH2:34][CH2:33][NH:32]2)[CH2:27][CH2:26]1>CN1C(=O)CCC1>[CH:21]([N:20]1[C:16]([C:10]2[N:11]=[C:12]3[C:13]4[CH:14]=[N:15][C:2]([N:32]5[CH2:33][CH2:34][CH2:35][CH:31]5[CH:28]5[CH2:27][CH2:26][N:25]([CH3:24])[CH2:30][CH2:29]5)=[CH:3][C:4]=4[O:5][CH2:6][CH2:7][N:8]3[CH:9]=2)=[N:17][CH:18]=[N:19]1)([CH3:23])[CH3:22]

Participants

Conditions

Temperature: 150 °C

Procedure

A mixture of 12-chloro-4-[1-(propan-2-yl)-1H-1,2,4-triazol-5-yl]-9-oxa-3,6,13-triazatricyclo[8.4.0.02,6]tetradeca-1(14),2,4,10,12-pentaene from Example 135 (160 mg, 0.480 mmol), TEA (0.50 mL), and 1-methyl-4-(pyrrolidin-2-yl)piperidine (161 mg, 0.960 mmol) in NMP (0.5 mL) was stirred at 150° C. for 24 h under nitrogen atmosphere. The resultant mixture was then purified by reverse phase combiflash eluting with a 0-50% gradient of CH3CN in 0.3% NH4HCO3 to give 106 (66 mg, 60% yield). LCMS (ESI): RT=4.11 min, m/z: 463.3 [M+H+]. 1H NMR (500 MHz, DMSO-d6): δ 9.08 (t, J=10.5 Hz, 1H), 7.90 (t, J=10.5 Hz, 1H), 7.84 (t, J=10 Hz, 1H), 5.98 (t, J=20 Hz, 2H), 4.52-4.47 (m, 4H), 4.10 (s, 1H), 3.45 (d, J=6.5 Hz, 1H), 2.78 (s, 1H), 2.11 (d, J=10 Hz, 3H), 1.93-1.66 (m, 8H), 1.50-1.39 (m, 7H), 1.31-1.27 (m, 3H)

Workup

customThe resultant mixture was then purified by reverse phase combiflash
washeluting with a 0-50% gradient of CH3CN in 0.3% NH4HCO3

Sources & evidence

ORD record: ord-70f2b3454438455990c6807cd612dab8
Source dataset: uspto-grants-2015_07
DOI: 10.6084/m9.figshare.5104873.v1
Patent number: US09090628B2

Reaction notes

Loading…